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Abstract 
Epigenome editing is an attractive way to manipulate gene expression. However, editing 
efficiencies depend on the DNA sequence context in a manner that remains poorly understood. 
Here we developed a novel system in which any protein can be recruited at will to a GFP reporter. 
We named it ParB/ANCHOR-mediated Inducible Targeting (PInT). Using PInT, we tested how 
CAG/CTG repeat size affects the ability of histone deacetylases to modulate gene expression. We 
found that repeat expansion reduces the effectiveness of silencing brought about by HDAC5 
targeting. This repeat-length specificity was abolished when we inhibited HDAC3 activity. Our 
data guide the use of these histone deacetylases in manipulating chromatin. PInT can be adapted 
to study the effect of virtually any sequence on epigenome editing. 
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Introduction: 
Chromatin structure impinges on every DNA-based transaction, from replication and DNA repair 
to transcription. Thus, it is not surprising that epigenome editing is being harnessed both to 
understand basic molecular mechanisms and to treat disease1. Epigenome editing is now most 
commonly carried out via the use of the domain of a chromatin modifier, or EpiEffector, fused to 
a catalytically dead Cas9 (dCas9). The fusion protein is targeted to a locus of choice by way of a 
customizable single guide RNA (sgRNA)2-10. Examples of dCas9-mediated epigenome editing 
include altering chromatin states by either targeting Krüppel-associated box (KRAB)6 or the 
histone acetyltransferase domain of p3002, thereby reducing or promoting enhancer function, 
respectively. Moreover, epigenome editing using Cas9-based approaches have been used to 
modify disease phenotypes in cells and in vivo11,12. 
It is currently not possible to predict whether targeting a specific locus with a particular dCas9-
EpiEffector fusion will result in efficient chromatin modification and alteration of gene 
expression. Several reasons have been proposed to account for this, ranging from the sequence 
of the sgRNA and the distance of its target from the transcriptional start site3-5, the chromatin 
structure already present at the target locus13-19, and/or the exact EpiEffector used2,4,10,17,19. 
Indeed, the same EpiEffector targeted at different loci can have very different effects10,17, 
highlighting that DNA context affects EpiEffectors in ways that are not understood.  
Some DNA sequences can have profound effects on nucleosome positioning and chromatin 
structure20. A prime example of this is the expansion of CAG/CTG repeats, which causes 14 
different neurological and neuromuscular diseases21,22. In healthy individuals, these sequences 
have less than 35 repeats at any one disease locus. However, they can expand and reach up to 
thousands of triplets. Once expanded, CAG/CTG repeats lead to changes in gene expression in 
their vicinity and to a heterochromatic-like state23-26. How these repetitive sequences might 
affect epigenome editing is unknown.   
Here, we developed a method to understand how DNA sequence context can influence 
epigenome editing efficiency. We named the system ParB/ANCHOR-mediated induced targeting 
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(PInT). With PInT, any protein of interest can be targeted near a sequence of choice. ParB, a 
bacterial protein, forms oligomers once it nucleates at its non-repetitive binding site, INT27. 
Fusing a protein of interest to ParB leads to the recruitment of many of the desired molecules to 
the INT locus. The targeting is inducible as we coupled ParB/ANCHOR to a chemically induced 
proximity (CIP) system derived from plants28. The target sequence is embedded in a GFP mini 
gene29 such that the effect of targeting on gene expression is easily monitored. Using PInT, we 
uncovered an unexpected effect of expanded CAG/CTG repeats on the effectiveness of histone 
deacetylase 5 (HDAC5) to modulate gene expression and found that this was due to the catalytic 
activity of HDAC3.  
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Results: 
ParB/ANCHOR-mediated induced targeting (PInT) 
We designed PInT (Fig. 1) to be modular and highly controllable. It contains a GFP mini gene that 
harbours two GFP exons flanking the intron of the mouse Pem1 gene29,30. A doxycycline-inducible 
TetOn promoter drives the expression of the reporter. This cassette is always inserted at the 
same genomic location as a single copy integrant in T-Rex Flp-In HEK293 cells. Inside the intron, 
we inserted a 1029 bp non-repetitive sequence, INT, that contains four binding sites for dimers 
of the Burkholderia cenocepacia ParB protein. Once bound to INT, ParB oligomerizes in a 
sequence-independent manner, recruiting up to 200 ParB molecules31. This ParB/ANCHOR 
system was first used in live yeast cells to visualize double-strand break repair27. More recently, 
it has been used to monitor the mobility of a genomic locus upon activation of transcription32 
and to visualize viral replication33 in live mammalian cells. We made the system inducible by 
fusing ParB to a plant protein called ABSCISIC ACID INSENSITIVE (ABI), which dimerizes with 
PYRABACTIN RESISTANCE1-LIKE (PYL) upon addition of abscisic acid (ABA) to the culture 
medium28. ABA is a plant hormone that is not toxic to human cells, making this CIP system 
especially convenient. Within 319bp of the INT sequence, there is a cloning site that can be used 
to insert any DNA motif. Thus, fusing any protein of interest to PYL allows for full temporal control 
over the recruitment of a protein of interest near a DNA sequence of choice. 
Fig. 1: Schematic of PInT. The GFP reporter is 
driven by an inducible Tet-On promoter. It 
contains an intron harbouring an INT sequence, 
which mediates the recruitment and 
oligomerization of ParB. We fused ParB to ABI, 
a plant protein that binds PYL only in the 
presence of abscisic acid (ABA). Fusing PYL to any protein of interest leads to its inducible recruitment 
319bp away from a cloning site that can be used to insert a sequence of choice. The PYL construct contains 
a 3xFLAG tag whereas the ParB-ABI fusion includes 3xHA. They both contain SV40 nuclear localization 
signals. 
 
It was important to determine whether the components of PInT affect the expression of the GFP 
reporter. We first tested whether ABA changed GFP expression in GFP(CAG)0 cells29. These cells 
carry the GFP mini gene without the INT sequence or any additional sequences in the intron (see 
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Table S1 and Fig. S1 for details on cell line construction). We found that treatment with up to at 
least 500 µM of ABA, which induces the dimerization between PYL and ABI, did not affect GFP 
expression (Fig. S2AB). We also transiently transfected GFP(CAG)0 cells with plasmids expressing 
the ParB-ABI fusion. This had no detectable effect on the behaviour of the reporter (Fig. S2C). We 
next inserted the INT sequence inside the Pem1 intron and integrated this construct using site-
directed recombination, generating GFP-INT cells. These cells contain INT but no additional 
sequence within the intron. They do not express ParB-ABI. We found that the insertion of the INT 
sequence had little, if any, discernable effect on the GFP expression (Fig. S2D). We conclude that 
by themselves, the individual components of PInT do not significantly interfere with GFP 
expression.  
We then stably integrated both the GFP-INT reporter and the ParB-ABI fusion to generate GFP-
INT-B cells. We found a decrease in GFP expression that correlated with high levels of ParB-ABI 
(Fig. S2EFG), suggesting that the binding of ParB-ABI has a predictable effect on the GFP reporter. 
To avoid any complication, we integrated ParB-ABI early in the construction pipeline such that all 
the cell lines presented here contain the same amount of ParB-ABI (Fig. S1). 
Next, we determined the efficiency of targeting PYL to the INT sequence and the consequences 
on GFP expression. We used nB-Y cells, which contain the GFP mini gene with the INT sequence, 
stably express both ParB-ABI (B) and PYL (Y), and contain n CAG repeats, in this case either 16, 
which is in the normal range, or an expanded repeat of 91 triplets (Fig. 2A, Fig. S3A). We found, 
using chromatin immunoprecipitation followed by qPCR (ChIP-qPCR), that only 0.1% of the input 
DNA could be precipitated when we treated the cells with the vehicle, DMSO, alone. By contrast, 
the addition of ABA to the cell media increased the association of PYL to the INT locus significantly, 
reaching 1.9 and 2.5% of the input chromatin pulled down in 16B-Y or 91B-Y cells, respectively 
(Fig. 2B). These results demonstrate the inducible nature of the system and show that the 
presence of the expansion does not interfere with the targeting efficiency. Importantly, PYL 
targeting had no effect on GFP expression as measured by flow cytometry (Fig. 2C). We conclude 
that PInT works as an inducible targeting system and that PYL targeting is efficient and does not 
further affect gene expression. 
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Fig. 2: Inducible targeting of PYL at the GFP 
reporter. A) Schematic representation of 16B-Y 
(left) and 91B-Y (right) cell lines. B) ChIP-qPCR 
using antibodies against FLAG to pull down PYL 
at INT and ACTA1 in 16B-Y cells (left, N=4) and 
91B-Y cells (right, N=4). The error bars 
represent the standard error. C) Representative 
flow cytometry profiles as well as quantification 
of the GFP expression in 16B-Y (left, N=6) and 
91B-Y (right, N=6) cells. The error bars are the 
standard deviation around the mean.  
HDAC5 silencing depends on CAG/CTG 
repeat size 
We next sought to test whether we could 
manipulate GFP expression using HDAC5. 
This class IIa deacetylase impacts gene 
silencing and heterochromatin 
maintenance34,35 as well as cell proliferation35,36. The PYL-HDAC5 fusion was functional since GFP-
INT cells transiently expressing this fusion had slightly lower GFP expression than those 
expressing PYL alone (Fig. S4A). We created isogenic nB-Y-HDAC5 cells that express stably a PYL-
HDAC5 fusion and have 16 or 59 CAG repeats within the GFP reporter (Fig. 3A). We found that 
adding ABA to these cells led to an increase in pull-down efficiency of PYL-HDAC5 at the INT locus 
from 0.06% to 2.2% in 16B-Y-HDAC5 cells and from 0.1% to 3% of input in the presence of 59 
repeats (Fig. 3B). This was accompanied by a significant 2-fold decrease in GFP expression in 59B-
Y-HDAC5 cells, whereas the decrease was of 3 folds in 16B-Y-HDAC5 cells (Fig. 3C, P=0.001 and 
P= 0.0015 using a paired Student’s t-test comparing conditions with ABA to those with DMSO 
only in 16B-Y-HDAC5 and 59B-Y-HDAC5 cells, respectively). Remarkably, the decrease in 
expression was significantly lower in the context of an expanded repeat (Fig. 3C, P=0.0001 
comparing the decrease in expression upon ABA addition between the 16B-Y-HDAC5 and 59B-Y-
HDAC5 using a Student’s t-test). Targeting efficiency of PYL-HDAC5 does not account for the 
repeat size-dependent effect since it was slightly higher in 59B-Y-HDAC5 than in 16B-Y-HDAC5 
cells (Fig. 3B). To determine whether the effect is due to targeting at the INT locus, we transiently 
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expressed PYL-HDAC5 in GFP(CAG)0B cells, which have no INT in their GFP reporter but express 
ParB-ABI. Adding ABA to these cells did not affect GFP expression (Fig. S4BC), suggesting that the 
presence of the INT sequence is essential. Moreover, PYL-HDAC5 targeting reduced the levels of 
acetylated histone H3 (acH3) (P=0.0001 and P=0.024 comparing DMSO treated and ABA-treated 
16B-Y-HDAC5 and 59B-Y-HDAC5, respectively, using a Student’s t-test), as measured by ChIP-
qPCR. The decrease in acH3 upon targeting was greater in 16B-Y-HDAC5 than in 16B-Y cells 
(P=0.006 using a Student’s t-test), consistent with a role for HDAC5 in silencing gene expression. 
Interestingly, the acH3 levels at the INT 
sequence were similar between 16B-Y and 
91B-Y and between 16B-Y-HDAC5 and 59B-
Y-HDAC5 (Fig. 3DE, P=0.95, and P=0.25, 
respectively using a Student’s t-test), 
suggesting that the acH3 levels are 
unaffected by the expansion. We conclude 
that PYL-HDAC5 targeting silences better 
the lines with the shorter repeats.  
Fig. 3: PYL-HDAC5 targeting induces silencing 
in a repeat-length dependent manner. A) 
Schematic representation of 16B-Y-HDAC5 (left) 
and 59B-Y-HDAC5 (right) cells. B) ChIP-qPCR 
using antibodies against FLAG to pull down PYL-
HDAC5 at INT and ACTA1 in 16B-Y-HDAC5 cells 
(left, N=4) and 59B-Y-HDAC5 cells (right, N=4). 
The error bars represent the standard error. C) 
Quantification of GFP expression upon 
incubation with ABA or DMSO in 16B-Y-HDAC5 
(left, N=6) and 59B-Y-HDAC5 (right, N=6) cells. 
The error bars show the standard deviation 
around the mean. D) ChIP-qPCR data using a 
pan-acetylated H3 antibody to pull down the 
INT and ACTA1 loci in 16B-Y-HDAC5 (left, N=4) 
and 59B-Y-HDAC5 (right, N=4) cells. The error 
bars represent the standard error. E) ChIP-qPCR 
data using a pan-acetylated H3 antibody to pull 
down the INT and ACTA1 loci in 16B-Y (left, N=4) 
and 91B-Y (right, N=4) cells. The error bars 
represent the standard error. 
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The N-terminal domain of HDAC5 mediates silencing 
Class I HDACs derive their catalytic activity in vitro from a conserved tyrosine residue that helps 
coordinate a zinc ion essential for catalysis37. By contrast, class IIa enzymes, like HDAC5, have a 
histidine instead of tyrosine at the analogous site, which considerably lowers HDAC activity37. In 
fact, the H1006Y mutant had more than 30-fold increase in its HDAC activity compared to the 
wild type enzyme37. To determine whether the catalytic activity of HDAC5 potentiates the 
decrease in GFP expression upon targeting, we compared the silencing activity of wild-type PYL-
HDAC5, the H1006A loss-of-function mutant, and the H1006Y gain-of-function mutant by 
transient transfection in 40B cells, which contain the GFP-INT reporter with 40 CAGs and express 
ParB-ABI (Fig. 4A). The effect on silencing seen upon targeting of the wild-type PYL-HDAC5 fusion 
was lower when delivered by transient transfection compared to the stable cell lines. 
Nevertheless, under these conditions, targeting PYL-HDAC5-H1006A or PYL-HDAC5-H1006Y 
could both silence the transgene compared to targeting PYL alone (Fig 4B; P= 0.01 and 0.0008, 
respectively, using a Student’s t-test), suggesting that tampering with the catalytic activity of 
HDAC5 does not influence silencing of our GFP reporter. Moreover, targeting PYL fused to the 
catalytic domain of HDAC5 did not shift GFP expression (Fig. 4B). Indeed, we find that the 
silencing activity was contained within the N-terminal part of HDAC5, which characterizes class 
IIa enzymes. Further truncations (Fig. 4AB) are consistent with a model by which the coiled-coil 
domain of HDAC5, which is responsible for homo and heterodimerization of class IIa enzymes in 
vitro38, contains the silencing activity.  
Fig. 4: The silencing activity of HDAC5 is contained in 
its N-terminal domain. A) Mutants and truncations of 
HDAC5 fused to PYL. The coiled-coil (CC) domain is 
indicated in purple, the deacetylase domain (HDAC) in 
orange. B) Ratio of the mean GFP intensities in 40B cells 
between ABA and DMSO only treatment of 40B cells 
transiently transfected with plasmids containing the 
constructs shown in A. Construct 1: N=7, P=0.0002 
versus PYL; construct 2: N=7, P=0.01 versus PYL; 
construct 3: N=7, P=0.0008 versus PYL; construct 4: N=7, 
P=0.88 versus PYL; construct 5: N=7, P=0.0012 versus 
PYL; construct 6: N=3, P=0.0003 versus PYL. In all cases, 
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we used a Student's t-test to calculate the P-values. The error bars show the standard deviation around 
the mean. *: P≤0.01 compared to PYL targeting. 
PYL-HDAC3 targeting enhances GFP expression independently of its catalytic activity 
HDAC5 is thought to mediate histone deacetylation by recruiting other HDACs, including HDAC339. 
Therefore, we hypothesized that PYL-HDAC3 targeting should have the same effect on GFP 
expression as PYL-HDAC5 targeting. To address this directly, we made a PYL-HDAC3 fusion and 
overexpressed it in 40B cells without targeting (Fig. S4D). We found that there was a slight 
decrease in GFP expression, suggesting that the construct could silence gene expression. Next, 
we generated nB-Y-HDAC3 cells and compared GFP intensities with and without ABA. Contrary 
to our initial hypothesis, we found that targeting PYL-HDAC3 in both 16B-Y-HDAC3 and 89B-Y-
HDAC3 increased GFP expression by 1.5 fold (Fig. S5AB, P=0.0004 and P=0.001 using paired 
Student’s t-tests comparing ABA and DMSO treatments in 16B-Y-HDAC3 and 89B-Y-HDAC3, 
respectively). The effect appeared direct since adding ABA to GFP(CAG)0B cells transiently 
expressing PYL-HDAC3 did not affect GFP expression (Fig. S4E). The increase in GFP expression in 
nB-Y-HDAC3 cells was accompanied by an efficient targeting of the PYL-HDAC3 fusion (Fig. S5C) 
and an increase in acH3 levels (Fig. S5D). However, treatment with the HDAC3-specific small 
molecule inhibitor RGFP96640 did not affect the increase in GFP expression in neither 16B-Y-
HDAC3 nor 89B-Y-HDAC3 cells (Fig. S5E). We conclude that targeting PYL-HDAC3 increases GFP 
expression independently of its HDAC activity, consistent with the observation that HDAC3 has 
an essential role during development that does not involve its HDAC activity41.  
HDAC3 activity is required for the repeat size-specificity upon HDAC5-mediated silencing 
Although HDAC3 targeting did not have the expected effect on GFP expression, evidence shows 
that its catalytic activity is implicated in HDAC5-mediated silencing39. To determine the potential 
catalytic role of HDAC3 in this context, we targeted PYL (Fig. 5A) or PYL-HDAC5 (Fig. 5B) to our 
GFP reporter in nB-Y and nB-Y-HDAC5 cells while cultivating the cells in the presence of RGFP966. 
We find that although this treatment had no effect on PYL targeting (Fig. 5A), it abolished the 
allele-length specificity of PYL-HDAC5 targeting, leading to a silencing efficiency of 2.4 and 2.5 
folds for 16B-Y-HDAC5 and 59B-Y-HDAC5, respectively (Fig. 5B, P= 0.77 using a Student’s t-test). 
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This is in contrast to the RGFP966-free conditions where targeting PYL-HDAC5 silenced better the 
normal-sized allele (Fig. 3). These results suggest that HDAC3 mediates the CAG repeat size-
dependency upon PYL-HDAC5 targeting.  
Fig. 5: HDAC3 activity is required for the allele-
specificity upon HDAC5-mediated silencing. A) 
Quantification of GFP intensity upon targeting in 
the presence of RGFP966 or the vehicle, DMSO, 
in 16B-Y (N=6) and 91B-Y cells (N=6). Note that 
the data for the DMSO-treated cells is the same 
as in Fig. 2C. The addition of DMSO did not affect 
GFP expression, and we therefore pooled the 
data. B) Quantification of GFP intensity upon 
targeting in the presence of RGFP966 or the vehicle, DMSO, in 16B-Y-HDAC5 (N=6) and 59B-Y-HDAC5 cells 
(N=6). Note that the data for the DMSO-treated cells is the same as in Fig. 3C. The addition of DMSO did 
not affect GFP expression, and we therefore pooled the data. The error bars show the standard deviation 
around the mean. 
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Discussion 
We presented here a novel assay to investigate the effect of a DNA sequence of interest on the 
efficiency of a chosen EpiEffector in altering gene expression. As an example of how the DNA 
context may affect the activity of an EpiEffector, we showed that expanded CAG/CTG repeats 
decrease the silencing efficiency of HDAC5. Moreover, we determined that this allele-length 
specificity depends on HDAC3 activity, highlighting the potential of PInT in uncovering unique 
mechanistic insights. These data provide evidence that local DNA sequence context is an 
important determinant of epigenome editing, independently of the efficiency or mode of 
targeting.  
PInT could be used for many different applications. First, the intron can host sequences beyond 
CAG/CTG repeats. Indeed, the GFP mini gene we used here, without the targeting components, 
was recently used to monitor the effect of a RNA polymerase III gene on  RNA polymerase II-
mediated transcription42. Second, it is often difficult to differentiate between a chromatin 
modifier changing gene expression because of a local effect on chromatin structure or indirectly 
through changes in the transcriptome. PInT allows making that distinction thanks to its inducible 
nature. Indeed, we found that overexpressing PYL-HDAC5 had a small effect on gene expression 
at the GFP reporter and that targeting it further decreased expression. We could conclude that 
PYL-HDAC5 can act locally to silence the transgene. This is useful in dissecting the mechanisms of 
action of EpiEffectors. Third, we demonstrated, using mutants and truncations of HDAC5, that 
we can quickly screen for protein domains and mutants that are most effective in modulating 
gene expression. Thus, PInT could be used to design peptides with sufficient activity to be useful 
in downstream epigenomic editing applications, for example when using dCas9 fusions in vivo. A 
current limitation of the S. pyogenes Cas9 for in vivo applications is its large size, which is at the 
limit of what adeno-associated viral vectors can accommodate43. Even with the smaller 
orthologues, fitting a dCas9 fusion inside a gene delivery vector is a challenge. Therefore, being 
able to trim an EpiEffector down to a small domain may help optimizing downstream applications 
and translation.  
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The observation that HDAC5 targeting has a differential effect on gene expression depending on 
the size of the repeat tract is surprising. Our data suggest that the deacetylase activity of HDAC3 
is required for this effect. Importantly, we cannot currently rule out that RGFP966 may inhibit 
other HDACs that would be responsible for this effect. Nevertheless, this small molecule is highly 
selective for HDAC340, making this HDAC the most likely candidate for driving allele-specific 
silencing. HDAC3 could be setting up an asymmetry between the two size alleles in several ways. 
For instance, it could deacetylate histones (those residues not recognized by the pan-acetylated 
histone H3 antibody that we used) or non-histone proteins in the vicinity of the expanded 
CAG/CTG repeat prior to HDAC5 targeting. More work is required to understand further the 
mechanism of the repeat length-specific silencing. 
Several studies have suggested that the ectopic insertion of an expanded CAG/CTG repeat in mice 
could induce changes in chromatin structure in the abutting sequences. An early example was 
the random insertion of arrays of transgenes, each carrying 192 CAGs44, which led to the silencing 
of the transgenes independently of the site of genomic integration. In addition, inserting a 40 kb 
human genomic region containing the DMPK gene along with an expansion of 600 CTGs45, or a 
13.5Kb region containing the human SCA7 gene with 92 CAGS46 all led to changes in chromatin 
marks near the expansion. It has been unclear, however, whether the presence of endogenous 
sequence elements, like CpG islands47 and CTCF binding sites26,48, is necessary for this effect. Our 
data show that 91 CAGs, without the flanking sequences normally present at the DMPK gene 
from whence this repeat was cloned49, does not lead to significant changes in the levels of 
acetylated histone H3 in its vicinity. These data suggest that the flanking sequence elements play 
important roles in the induction and/or maintenance of heterochromatic marks surrounding 
expanded CAG/CTG repeats. 
Recently, a number of studies have proposed that silencing the expanded repeat allele without 
affecting the expression of the normally sized allele may lead to a novel therapeutic approach for 
expanded CAG/CTG repeats50-52. However, only one factor, which is essential for mouse 
development52, has been identified so far. We speculate that PInT may be adapted to screen for 
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allele length-specific silencers, which could help uncover novel therapeutic options for expanded 
CAG/CTG repeat disorders. 
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Materials and Methods 
Cell culture conditions and cell line construction 
The majority of the cell lines used, including all the parental lines, were genotyped by Microsynth, 
AG (Switzerland) and found to be HEK293.2sus. They were free of mycoplasma as assayed by the 
Mycoplasma check service of GATC Biotech. The cells were maintained in DMEM containing 10% 
FBS, penicillin, and streptomycin, as well as the appropriate selection markers at the following 
concentrations: 15 µg ml-1 blasticidin, 1µg ml-1 puromycin, 150µg ml-1 hygromycin, 400 µg ml-1 
G418, and/or 400 µg ml-1 zeocin. The incubators were set at 37 °C with 5% CO2. Whereas FBS was 
used to maintain the cells, dialyzed calf serum was used at the same concentration for all the 
experiments presented here. The ABA concentration used was 500 µM, unless otherwise 
indicated. Doxycycline (dox) was used at a concentration of 2 µg ml-1 in all experiments. 
A schematic of cell line construction and pedigree is found in Figure S1, and the lines are listed in 
Table S1. This table includes the plasmids made for cell line construction. The plasmids used for 
transient transfections are found in Table S2. For each cell line, single clones were picked and 
tested for expression of ParB-ABI and PYL-fusions by western blotting using the protocol 
described before30. Briefly, whole cell extracts were obtained, and their protein content was 
quantified using the Pierce BCA Protein Assay Kit (ThermoScientific). Proteins were then run onto 
Tris-glycine 10% SDS PAGE gels before being transferred onto nitrocellulose membrane 
(Axonlab). The membranes were blocked using the Blocking Buffer for Fluorescent Western 
Blotting (Rockland), and primary antibodies were added overnight. Membranes were then 
washed followed by the addition of the secondary antibody (diluted 1 to 2000). The fluorescent 
signal was detected using an Odyssey Imaging System (Li-CoR). All antibodies used are found in 
Table S3. To assess repeat sizes, we amplified the repeat tracts using oVIN-0459 and oVIN-0460 
with the UNG and dUTP-containing PCR as described53 and then Sanger-sequenced by Microsynth 
AG (Switzerland). The sequences of all the primers used in this study are found in Table S4. 
The ParB-INT sequence system used here is the c2 version described previsouly27, except that the 
ParB protein was codon-optimized for expression in human cells. It is also called ANCHOR1 and 
is distributed by NeoVirTech. ParB-ABI (pBY-008), PYL (pAB-NEO-PYL), PYL-HDAC5 (pAB(EXPR-
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PYL-HDAC5-NEO)) and PYL-HDAC3 (pAB(EXPR-PYL-HDAC3-NEO)) constructs were randomly 
inserted and single clones were then isolated (Table S1). GFP-reporter cassettes were inserted 
using Flp-mediated recombination according to the manufacturer’s instruction (Thermo 
Scientific). Single colonies were picked and screened for zeocin sensitivity to ensure that the 
insertion site was correct. 
Targeting assays 
For targeting assays involving transient transfections, cells were plated onto poly-D-lysine-coated 
12-well plates at a density of 6x105 cells per well and transfected using 1 µg of DNA per well and 
Lipofectamine 2000 or Lipofectamine 3000 (Thermofisher Scientific). 6 hours after transfection, 
the medium was replaced with one containing dox and ABA or DMSO. 48h after the transfection, 
the cells were split, and fresh medium with dox and ABA or DMSO was replenished. On the fifth 
day, samples were detached from the plate with PBS + 1 mM EDTA for flow cytometry analysis.  
In the case of the stable cell lines, cells were seeded at a density of 4x105  per well in 12-well 
plates. The media included dox and ABA or DMSO. The medium was changed 48 hours later and 
left to grow for another 48 hours. The cells were then resuspended in 500µl PBS + 1 mM EDTA 
for flow cytometry analysis.  
Flow cytometry and analysis 
We used an Accuri C6 flow cytometer from BD and measured the fluorescence in at least 12 500 
cells for each treatment. The raw data was exported as FCS files and analyzed using FlowJo 
version 10.0.8r1.  
Chromatin immunoprecipitation 
For chromatin immunoprecipitation, the cells were treated as for the targeting experiments 
except that we used 10 cm dishes and 4x106 cells. After 96 hours of incubation, 
paraformaldehyde was added to the medium to a final concentration of 1% and the cells were 
incubated for 10 minutes at room temperature. The samples were then quenched with 0.125 M 
PBS-glycine for 5 minutes at room temperature. Samples were then centrifuged, the supernatant 
was discarded, and the cell pellets were washed with ice-cold PBS twice. The samples were split 
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into 107 cell aliquots and either used immediately or stored -75 °C for later use. Sonication was 
done using a Bioruptor for 25 to 30 min. DNA shearing was visualized by agarose gel 
electrophoresis after crosslink reversal and RNase treatment. 20% of sonicated supernatant was 
used per IP, with 3 μg anti-FLAG (M2, Sigma), anti-PAN acetylated H3 (Merck), or anti-IgG (3E8, 
Santa Cruz Biotechnology) on Protein G Sepharose 4 Fast Flow beads (GE healthcare). The 
samples were incubated at 4°C overnight and then washed with progressively more stringent 
conditions. After the IP, the samples were de-crosslinked and purified using a QIAquick PCR 
purification kit (Qiagen) and analyzed using a qPCR. 
Quantitative PCR 
Quantitative PCR was performed with the FastStart Universal SYBR Green Master Mix (Roche) 
using a 7900HT Fast Real-Time PCR System in a 384-Well Block Module (Applied Biosystems™). 
Primers used to detect enrichment at the INT sequence and at ACTA1 gene are listed in Table S4. 
Ct values were analyzed using the SDS Software v2.4. The percentage of input reported was 
obtained by dividing the amount of precipitated DNA for the locus of interest by the amount in 
the input samples multiplied by 100%.  
Statistics 
We determined statistical significance in the targeting experiments using a two-tailed paired 
Student’s t-test because the samples treated with DMSO and ABA were from the same original 
population and treated side-by-side. For the ChIP samples, the test used was a two-tailed 
Student’s t-test. All the statistical analyses were done using R studio version 3.4.0. We concluded 
that there was a significant difference when P < 0.05.  
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Table S1: Cell lines 
Cell line 
name 
Parent cell 
line 
Transgenes Plasmid used Integration method 
Resistance 
marker 
Reference 
T-REX Flp-in HEK293 
pFRT/lacZeo            - - 
Blasticidin 
Zeocin 
Thermo 
Fisher Tetracycline 
Repressor 
pcDNA6/TR 
 
- 
GFP(CAG)0 T-REX Flp-in GFP(CAG)0 pGFP(CAG)0 
Flp-mediated 
integration 
Blasticidin 
Hygromycin 
29 
GFP(CAG)0B GFP(CAG)0 
GFP(CAG)0 pGFP(CAG)0 
Flp-mediated 
integration Blasticidin 
Puromycin 
Hygromycin 
This study 
ParB-ABI* pBY-008 Random integration 
GFP-INT T-REX Flp-in GFP-INT-CAG0 pVIN-221 
Flp-mediated 
integration 
Blasticidin 
Hygromycin 
This study 
GFP-INT-B GFP-INT 
GFP-INT-CAG0 pVIN-221 
Site specific 
insertion Blasticidin 
Puromycin 
Hygromycin 
This study 
ParB-ABI* pBY-008 Random integration 
GFP-INT-40 T-REX Flp-in GFP-INT-CAG40 pVIN-117 
Flp-mediated 
integration 
Blasticidin 
Hygromycin 
This study 
40-B GFP-INT-40 
GFP-INT-CAG40 pVIN-117 
Site specific 
insertion Blasticidin 
Puromycin 
Hygromycin 
This study 
ParB-ABI* pBY-008 Random integration 
HEKB T-REX Flp-in ParB-ABI* pBY-008 Random integration 
Blasticidin 
Zeocin 
Puromycin 
This study 
HEKB-Y HEKB 
ParB-ABI* pBY-008 
Random integration 
Blasticidin 
Zeocin 
Puromycin 
Neomycin 
This study 
PYL† 
pAB-NEO-
PYL 
16B-Y HEKB-Y 
ParB-ABI* pBY-008 
Random integration Blasticidin 
Puromycin 
Neomycin 
Hygromycin 
This study PYL† 
pAB-NEO-
PYL 
GFP-INT-CAG16 pBY-050 
Flp-mediated 
integration 
91B-Y HEKB-Y 
ParB-ABI* pBY-008 
Random integration Blasticidin 
Puromycin 
Neomycin 
Hygromycin 
This study PYL† 
pAB-NEO-
PYL 
GFP-INT-CAG89 pBY-018 
Flp-mediated 
integration 
*: Contains 3xHA tag and a NLS. †: Contains 3xFLAG and a NLS. 
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Table S1 (continued): Cell lines 
Cell line 
name 
Parent cell 
line 
Transgenes Plasmid used Integration method 
Resistance 
marker 
Reference 
HEKB-Y-
HDAC3 
HEKB 
ParB-ABI* pBY-008 
Random integration 
Blasticidin 
Zeocin 
Puromycin 
Neomycin 
This study 
PYL-HDAC3† 
pAB(EXPR-PYL-HDAC3-
NEO) 
16B-Y-
HDAC3 
HEKB-Y-
HDAC3 
ParB-ABI* pBY-008 
Random integration Blasticidin 
Puromycin 
Neomycin 
Hygromycin 
This study PYL-HDAC3† 
pAB(EXPR-PYL-HDAC3-
NEO) 
GFP-INT-
CAG16 
pBY-050 
Flp-mediated 
integration 
89B-Y-
HDAC3 
HEKB-Y-
HDAC3 
ParB-ABI* pBY-008 
Random integration Blasticidin 
Puromycin 
Neomycin 
Hygromycin 
This study PYL-HDAC3† 
pAB(EXPR-PYL-HDAC3-
NEO) 
GFP-INT-
CAG89 
pBY-018 
Flp-mediated 
integration 
HEKB-Y-
HDAC5 
HEKB 
ParB-ABI* pBY-008 
Random integration 
Blasticidin 
Zeocin 
Puromycin 
Neomycin 
This study 
PYL-HDAC5† 
pAB(EXPR-PYL-HDAC5-
NEO) 
16B-Y-
HDAC5 
HEKB-Y-
HDAC5 
ParB-ABI* pBY-008 
Random integration Blasticidin 
Puromycin 
Neomycin 
Hygromycin 
This study PYL-HDAC5† 
pAB(EXPR-PYL-HDAC5-
NEO) 
GFP-INT-
CAG16 
pBY-050 
Flp-mediated 
integration 
59B-Y-
HDAC5 
HEKB-Y-
HDAC5 
ParB-ABI* pBY-008 
Random integration Blasticidin 
Puromycin 
Neomycin 
Hygromycin 
This study PYL-HDAC5† 
pAB(EXPR-PYL-HDAC5-
NEO) 
GFP-INT-
CAG59 
pBY-018 
Flp-mediated 
integration 
*: Contains 3xHA tag and a NLS. †: Contains 3xFLAG and a NLS. 
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Table S2: Plasmids used for transient transfection experiments 
Name Description Source 
pBY-008 Expresses ParB-ABI with 3xHA and a SV40 NLS 
This 
study 
pBY-022 
Expresses PYL fused to 3xFLAG and a SV40 NLS. Also serves 
as a destination vector for making fusions 
This 
study 
pBY-006 Expresses PYL-HDAC3 with 3xFLAG and a SV40 NLS  
This 
study 
pBY-017 Expresses PYL-HDAC5 with 3xFLAG and a SV40 NLS 
This 
study 
pAB-HDAC5(mut-H-A) Expresses PYL-HDAC5 H1006A with 3xFLAG and a SV40 NLS 
This 
study 
pAB-HDAC5(mut-H-Y) Expresses PYL-HDAC5 H1006Y with 3xFLAG and a SV40 NLS 
This 
study 
pAB(EXPR-HDAC5-trunc1) 
Expresses PYL-HDAC5 aa 1-275 with 3xFLAG and a SV40 
NLS 
This 
study 
pAB-EXPR(PYL-
cat_dom_HDAC5) 
Expresses the PYL-HDAC5 catalytic domain with 3xFLAG 
and a SV40 NLS  
This 
study 
pAB-EXPR(PYL-
Nterm_dom_HDAC5) 
Expresses the PYL-HDAC5 N terminal domain fused to 
3xFLAG and a SV40 NLS 
This 
study 
 
Table S3: Antibodies 
Epitope Company Catalog number Dilution Assay 
FLAG Sigma-Aldrich F1804-5MG 
3 μg per IP ChIP 
1:1000 WB 
IgG Santa Cruz Biotechnology sc-69786 3 μg per IP ChIP 
Pan-acetylation of H3 Merck #06-599 3 μg per IP ChIP 
Histone H3 Abcam ab1791 3 μg per IP ChIP 
Actin Sigma-Aldrich A2066-.2ML 1:2000 WB 
 
Table S4: Primers for qPCR and to verify repeat size 
Oligo Sequence Targeted locus Reference 
oVIN-0459 5’ AAGAGCTTCCCTTTACACAACG GFP transgene 30 
oVIN-0460 5’ TCTGCAAATTCAGTGATGC GFP transgene 30 
oVIN-0969 5’ TGAATACCATGCGCTCTA INT This study 
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oVIN-0970 5’ GCCGTTCGTGGCAGAGAT INT This study 
oVIN-1075 5’ AGCGCGGCTACAGCTTCAC ACTA1 This study 
oVIN-1076 5’ CAGCCGTGGCCATCTCTT ACTA1 This study 
 
Fig. S1. Parentage of the cell lines described in this study. All cell lines are clonal. 
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Fig. S2. Effect of components of PInT on GFP expression. A) Cartoon of cell lines used. B) Representative 
flow cytometry profiles of GFP(CAG)0 cells treated with increasing concentrations of ABA dissolved into 
the same volume of DMSO. C) Representative flow cytometry profiles of GFP(CAG)0 cell lines transfected 
with a plasmid expressing ParB-ABI or an empty vector. D) Comparison of GFP expression between 
GFP(CAG)0 and GFP-INT cells. E) Western blots (against HA) of GFP-INT-B clones showing varying amounts 
of ParB-ABI in the different clones. F) Flow cytometry profiles of GFP-INT-B clone #4, which expresses low 
levels of ParB-ABI. G) Representative flow cytometry profile of GFP-INT-B clone #21  expressing a larger 
amount of ParB-ABI. Note that the GFP-INT parent profile is the same in panels F and G because the GFP 
expression of both clones was done on the same day using the same parent cell line control.   
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Fig. S3. Cell line making and characterization. The levels of ParB-ABI and PYL-fusions by western blotting 
using antibodies against HA and FLAG, respectively. The red boxes identify the clones that were used 
subsequently. A) ParB-ABI levels in HEKB clones. B) PYL levels in HEKBY cells. C) PYL-HDAC5 levels in HEKB-
Y-HDAC5 cells. D) PYL-HDAC5 and ParB-ABI levels in 16B-Y-HDAC5 and 59B-Y-HDAC5 cells. nB-Y-FI cells 
will be characterized elsewhere. E) PYL-HDAC3 levels in HEKBYH3 cells. F) PYL-HDAC3 and ParB-ABI levels 
in 16B-Y-HDAC3 and 89B-Y-HDAC3 cells. 
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Fig. S4. The functionality of PYL fusions in GFP-INT-B cells and GFP(CAG)0B cells. Representative flow 
cytometry profiles after transient overexpression of PYL and PYL-HDAC5 in GFP-INT-B cells (A), or of PYL 
and PYL-HDAC3 in GFP-INT-B cells (B). C-E) Representative flow cytometry profiles of GFP(CAG)0B cells 
transiently transfected with PYL (C), PYL-HDAC5 (D), or PYL-HDAC3 (E) and incubated with DMSO or ABA.  
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Fig. S5. Targeting of PYL-HDAC3 increases GFP 
expression independently of its catalytic 
activity. A) Schematic representation of the 
nB-Y-HDAC3 cells. B) Quantification of GFP 
expression in nB-Y-HDAC3 cells with ABA or 
DMSO (16B-Y-HDAC3: N=4; 89B-Y-HDAC3: 
N=4). The error bars are the standard error 
around the indicated mean. C) ChIP-qPCR 
experiments using an antibody against PYL-
HDAC3 fusion (FLAG) at the INT and ACTA1 loci 
in the presence of ABA or DMSO. Left, 16B-Y-
HDAC3 cells (N=4), Right, 89B-Y-HDAC3 cells 
(N=4). The error bars are the standard error. D) 
ChIP-qPCR experiments using an antibody 
against pan-acetylated H3 (acH3) at the INT 
and ACTA1 loci in the presence of ABA or 
DMSO. Left, 16B-Y-HDAC3 cells (N=4), Right, 
89B-Y-HDAC3 cells (N=4). The error bars are 
the standard error. E) Quantification of GFP 
expression in nBYH3 cells with ABA or DMSO 
and treated with RGFP966 (16B-Y-HDAC3: N=4; 
89B-Y-HDAC3: N=4). The error bars are the 
standard error around the indicated mean. 
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Fig. S6: Unaltered full western blots. Black boxes indicate where the blots were cropped. 
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